Drugs / Anti-BCMA chimeric antigen receptor autologous T cells
Anti-BCMA chimeric antigen receptor autologous T cells
also known as
Targeted BCMA Autologous CART Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07626476 | Dec 2024 → Dec 2027 expected | AL amyloidosis | Beijing Boren Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-BCMA chimeric antigen receptor autologous T cells | “Anti-BCMA chimeric antigen receptor autologous T cells are a BCMA-targeted, gene-modified autologous T-cell (CAR-T cell) immunotherapy derived from the participant's autologous...” NCT07626476 ↗ |
| Known as | Targeted BCMA Autologous CART Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07626476 ↗ |
| Modality | Cell therapy | “gene-modified autologous T-cell (CAR-T cell) immunotherapy” NCT07626476 ↗ |
| Route | Intravenous | “administered as an injection by a single intravenous infusion” NCT07626476 ↗ |